All In Biotech

Drug Trial Radar · NCT04745832

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study

Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

82

Actual

Start

Aug 13, 2021

Primary completion

Mar 20, 2023

Study completion Mar 20, 2023

Sponsor

Lead sponsor
MEI Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Kyowa Kirin, Inc.
First posted
Feb 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.

Conditions

  • Follicular Lymphoma (FL)
  • Non Hodgkin Lymphoma
  • Marginal Zone Lymphoma

Interventions

  • ZandelisibDrug

    Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3

  • RituximabDrug

    Rituximab IV 375 mg/m2 for 6 cycles

  • BendamustineDrug

    Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles

  • CHOPDrug

    Cyclophosphamide, Vindcristine IV, and Prednisone daily orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 1 year 7 months

Locations

141 sites in 19 countries. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope and Innovation

    Tucson, Arizona

  • Orange Coast Memorial Medical Center

    Fountain Valley, California

  • Long Beach Memorial Medical Center

    Long Beach, California

  • The Oncology Institute of Hope and Innovation

    Riverside, California

  • BRCR Medical Center Inc

    Hollywood, Florida

  • Henry Ford Hospital

    Detroit, Michigan

  • Revive Research Institute

    Farmington Hills, Michigan

  • Revive Research Institute

    Sterling Heights, Michigan

  • Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center

    Springfield, Missouri

  • Inspira Medical Center Mullica Hill

    Mullica Hill, New Jersey

  • MetroHealth Medical Center

    Cleveland, Ohio

  • Alpha Research Institute, LLC

    Baytown, Texas

  • Valley Cancer Associates

    Harlingen, Texas

  • Community Cancer Trials of Utah

    Ogden, Utah

  • Canberra Hospital

    Garran, Australia

  • The Perth Blood Institute (PBI)

    West Perth, Australia

  • Westmead Hospital

    Westmead, Australia

  • AZ Sint-Jan Burgge-Oostende AV

    Bruges, Belgium

  • UZ Brussel

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Center Hospitalier de Jolimont

    Haine-Saint-Paul, Belgium

  • UZ Leuven Campus Gasthuisberg

    Leuven, Belgium

  • McGill University Health Centre

    Québec, Canada

  • Eastern Regional Health Authority

    St. John's, Newfoundland and Labrador, Canada

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie

    Sherbrooke, Quebec, Canada

  • CHU Estaing. Service d'hématologie clinique et de thérapie cellulaire adulte,

    Clermont-Ferrand, France

  • Centre Hospitalier De Dunkerque - Service d'hématologie

    Le Mans, France

  • Centre Hospitalier du Mans

    Le Mans, France

  • Centre Leon Berard

    Lyon, France

  • Hôpital Saint-Louis

    Paris, France

  • CHU de Bordeaux - Maladies Du Sang, Centre François Magendie

    Pessac, France

  • Centre Henri Becquerel, Service d'Hematologie

    Rouen, France

  • CHU de Tours, Hôpital Bretonneau Centre

    Tours, France

  • Institut De Cancerologie Gustave Roussy

    Villejuif, France

  • LTD Israeli-Georgian Medical Research Clinic "Helsicore"

    Tbilisi, Georgia

  • M. Zodelava Hematology Center

    Tbilisi, Georgia

  • J.S.C. K. Eristavi National Center of Experimental and Clinic

    Tbilisi, Georgia

  • LTD "Medinvest" Institute of Hematology and Transfusiology

    Tbilisi, Georgia

  • General Hospital of Athens "Laiko", Department of Haematology and Bone Marrow Transplantation

    Athens, Greece

  • University General Hospital of Ioannina, Department of Haematology

    Ioannina, Greece

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.